Caris Life Sciences, Inc. (CAI) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Analysis Summary
Caris Life Sciences, Inc. reported revenue of $812.0M in the most recent fiscal year, growing at a 5-year CAGR of 14.3%.
Trailing-twelve-month margins: gross margin 69.7%, operating margin 15.5%, net margin 10.6%.
At the current price of $31.02, CAI trades at a P/E of 85.99 and an ROE of 18.77%. Market capitalisation stands at $8.8B.
Balance sheet quality for CAI: current ratio of 7.8, net cash position of $421.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $31.02 |
| Market Cap | $8.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 85.99 |
| Price / Book | 15.29 |
| EV / EBITDA | 45.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 18.77% |
| Return on Invested Capital | 14.67% |
| Return on Assets | 8.55% |
| Gross Margin | 69.66% |
| Operating Margin | 15.49% |
| Net Margin | 10.62% |
Financial Health
| Debt / Equity | 0.76 |
| Current Ratio | 5.53 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 6.95 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.2B | 29.72 | -56.6% | |
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price Performance
| 1 month | +46.86% |
| 3 months | +66.74% |
| Year-to-date | +14.14% |
| 1 year | -8.15% |
52-Week Range
| 52-week High | $34.54 |
| 52-week Low | $14.19 |
| Avg Volume (90d) | 4.0M |
Related companies: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of CAI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks